The current case series clarified the efficacy of ALK-TKIs, including alectinib, a second-generation ALK-TKI, across different tumor types and fusion partners in patients with advanced, ALK-rearranged, nonlung solid tumors. This evidence concerns the gene ALK and neoplasm.